share_log

XBiotech Halts Rheumatology Program After Phase II Rheumatoid Arthritis Study Fails To Meet Primary Endpoint Amid Data Irregularities; Future Studies On Hold Pending Further Analysis Of Findings

XBiotech Halts Rheumatology Program After Phase II Rheumatoid Arthritis Study Fails To Meet Primary Endpoint Amid Data Irregularities; Future Studies On Hold Pending Further Analysis Of Findings

XBiotech暂停风湿病项目,此前II期类风湿关节炎研究未能满足主要终点,数据出现不规律;未来研究持有,待进一步分析结果。
Benzinga ·  12/23 22:03

XBiotech Halts Rheumatology Program After Phase II Rheumatoid Arthritis Study Fails To Meet Primary Endpoint Amid Data Irregularities; Future Studies On Hold Pending Further Analysis Of Findings

XBiotech暂停风湿病项目,此前II期类风湿关节炎研究未能满足主要终点,数据出现不规律;未来研究持有,待进一步分析结果。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发